Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan buys chin fat firm Kythera for $2.1bn

This article was originally published in Scrip

Executive Summary

Allergan is now geared up to treat all signs of facial aging, it claims. The Irish-headquartered firm is to buy Kythera Biopharmaceuticals and its approved submental fullness (double chin) drug Kybella (ATX-101) for $75 per Kythera share, or around $2.1bn. The drug, which has a US launch slated for the third quarter of this year, will slot neatly into Allergan's facial aesthetics portfolio, which includes Botox, and serve as a "pivotal entry point for expanding the use of facial aesthetic products in men," hopes Allergan.

Advertisement

Related Content

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain
Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
Allergan Confident About Continued Growth, Swats Down Competition Concerns
Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Led By Former Kythera Executives, Unity Raises $116m To Make Aging Less Painful
VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
Biotech VC Funding Rises As Fewer Companies Get More Dollars

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel